Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Idea to Innovation

Carleton University

$20,000.00

Lab2Market: A novel strategy towards the computational development of peptide 'disruptors' to be used as molecular probes or therapeutic molecules.

FY 2021-22

Summary
Through the Lab2Market partner program, we are proposing to bring to market software that enables rapid screening and development of novel peptide therapeutics. Indeed, the front runners in the game of drug delivery include small molecule and large molecule drugs, but there is another class that lands right in between; peptides. Since the introduction of insulin peptides for the treatment of diabetes in 1921, more than 100 peptide drugs have reached the market for a number of diseases, including cancer, multiple sclerosis, HIV infection, and chronic pain (10 peptides since 2017). New market growth into peptide therapeutics has resulted in >150 peptides in clinical development and another >600 peptides undergoing preclinical studies. The market is growing faster than any other therapeutics and is estimated at >$40 billion per year, with a double approval rate compared to small molecule drugs. To directly address challenges in generating new peptides to permit market growth, we have developed TIPS (The In silico Peptide Synthesizer), a computational method for developing peptide-based inhibitors. This computational pipeline promises to decrease the time and research screening costs to efficiently design target-specific inhibitors. Our objective is to carry out a Market Assessment to determine appropriate strategies to license our software to key industry partners.
Program
Idea to Innovation
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
571233-2022
Name nom
Biggar, Kyle
Department département
Biochemistry, Institute of
Organization id
23
Institution établissement
Carleton University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2022
Award amount
20000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Installment
inst:1
Partie
1
Nb partie
1
Application title
Lab2Market: A novel strategy towards the computational development of peptide 'disruptors' to be used as molecular probes or therapeutic molecules.
Keyword
NSERC
Application summary
Through the Lab2Market partner program, we are proposing to bring to market software that enables rapid screening and development of novel peptide therapeutics. Indeed, the front runners in the game of drug delivery include small molecule and large molecule drugs, but there is another class that lands right in between; peptides. Since the introduction of insulin peptides for the treatment of diabetes in 1921, more than 100 peptide drugs have reached the market for a number of diseases, including cancer, multiple sclerosis, HIV infection, and chronic pain (10 peptides since 2017). New market growth into peptide therapeutics has resulted in >150 peptides in clinical development and another >600 peptides undergoing preclinical studies. The market is growing faster than any other therapeutics and is estimated at >$40 billion per year, with a double approval rate compared to small molecule drugs. To directly address challenges in generating new peptides to permit market growth, we have developed TIPS (The In silico Peptide Synthesizer), a computational method for developing peptide-based inhibitors. This computational pipeline promises to decrease the time and research screening costs to efficiently design target-specific inhibitors. Our objective is to carry out a Market Assessment to determine appropriate strategies to license our software to key industry partners.